Form 4: Elanco Director Defers Fees into Stock Units

Elanco Animal Health Director Kapila K. Anand deferred cash retainer fees into 381.1312 Deferred Stock Units, increasing her beneficial ownership to 8,894.7414 units.

Summary

• Kapila K. Anand, a Director at Elanco Animal Health Inc., acquired 381.1312 Deferred Stock Units.
• This transaction occurred on December 31, 2025, and represents a deferral of her director cash retainer fees.
• The Deferred Stock Units were valued at $22.63 per unit, based on the closing price of Elanco common stock on the grant date.
• Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock.
• These units will be settled in stock upon Ms. Anand's separation of service from the Company's Board of Directors.
• Following this transaction, Ms. Anand beneficially owns a total of 8,894.7414 Deferred Stock Units.

Sentiment

Score: 7

Explanation: The deferral of cash compensation into equity by a director is generally viewed positively as it aligns the director's interests with shareholders and demonstrates confidence in the company's long-term prospects. It's a routine, positive governance action.

Positives

• Director Kapila K. Anand is increasing her beneficial ownership in Elanco Animal Health Inc. through the deferral of cash fees into stock units.
• The deferral plan aligns the director's interests with those of shareholders by linking compensation to company stock performance.
• The acquisition of 381.1312 Deferred Stock Units at a price of $22.63 per unit demonstrates continued commitment to the company.

Future Outlook

The Deferred Stock Units acquired by Director Anand will be settled in Elanco common stock upon her separation of service from the company's Board of Directors, aligning future compensation with long-term company performance.

Industry Context

This transaction reflects a common practice in corporate governance where directors elect to defer cash compensation into equity, aligning their financial interests with the long-term performance of the company within the animal health industry.

Comparison to Industry Standards

• Deferring director fees into equity is a standard practice across many industries, including the animal health sector, and is often seen as a positive indicator of management's belief in the company's future.
• Companies like Zoetis Inc. (ZTS) and IDEXX Laboratories, Inc. (IDXX) also utilize similar equity-based compensation plans for their directors to foster long-term alignment.

Corporate Governance

Stakeholder Impact

• Shareholders: Increased alignment of director's interests with shareholders, potentially fostering more long-term strategic decisions.

Next Steps

• The Deferred Stock Units will be settled in Elanco common stock upon Ms. Anand's separation of service from the Board of Directors.

Key Dates

Recommendation

This Form 4 reports a routine deferral of director fees into stock units, which is a positive sign of alignment but not a material event that would significantly alter the investment thesis for Elanco Animal Health. It reinforces a 'hold' stance, indicating continued confidence in the company's governance and long-term strategy without providing new catalysts for a 'buy' or 'sell' recommendation.

Keywords

Elanco Animal Health, ELAN, Kapila K. Anand, Director Compensation, Deferred Stock Units, Insider Ownership, SEC Form 4, Stock Deferral Plan